Clinical Trial

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and efficacy of HS-20093 in combination with other anti-cancer agents in patients with advanced metastatic colorectal cancer.
Trial Details
NCT Number NCT06825624
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Metastatic Colorectal Cancer (CRC)
Enrollment 560 participants
Start Date 2024-10-03
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-13